Vandetanib Plus Pemetrexed Versus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (Nsclc): A Randomized, Double-Blind Phase Iii Trial (Zeal)

腫瘤醫學研究所YANG, CHIH-HSINCHIH-HSINYANG2011-06-242018-07-092011-06-242018-07-092009http://ntur.lib.ntu.edu.tw//handle/246246/235721en-US[SDGs]SDG3Vandetanib Plus Pemetrexed Versus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (Nsclc): A Randomized, Double-Blind Phase Iii Trial (Zeal)